Viral Hepatitis

• CLINICAL_TRIALS withdrawal · 2024-11-19
  Clinical Trial Update: Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry

  A registry trial evaluating endoscopic ultrasound-guided liver biopsy and portal pressure measurements has been withdrawn from ClinicalTrial…

• EMA withdrawal · 2023-11-07
  EMA Withdrawn: Rebetol (ribavirin) — Merck Sharp and Dohme B.V

  EMA withdrew Rebetol (ribavirin) from the market.

• EMA withdrawal · 2022-12-15
  EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.

  The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.

• EMA withdrawal · 2021-07-09
  EMA Withdrawn: Ribavirin Teva Pharma B.V. (ribavirin) — Teva B.V.

  The EMA withdrew Ribavirin Teva Pharma B.V. (ribavirin) from the market in June 2021.

• EMA withdrawal · 2021-07-09
  EMA Withdrawn: Ribavirin Teva (ribavirin) — Teva B.V.

  Ribavirin Teva has been withdrawn from the European market.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2020-11-23
  EMA Withdrawn: Ribavirin Mylan (previously Ribavirin Three Rivers) (ribavirin) — Mylan S.A.S

  The EMA has withdrawn Ribavirin Mylan (ribavirin) from the market (formerly Ribavirin Three Rivers).

• EMA withdrawal · 2016-10-24
  EMA Application withdrawn: Cokiera — AbbVie Ltd

  EMA has withdrawn the application for Cokiera by AbbVie Ltd.

• EMA withdrawal · 2013-05-06
  EMA Lapsed: Ribavirin BioPartners (ribavirin) — BioPartners GmbH

  EMA status indicates ribavirin product by BioPartners GmbH has lapsed (withdrawn).